Cited 1148 times in
Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 정준 | - |
dc.contributor.author | 박병우 | - |
dc.date.accessioned | 2018-07-20T07:37:25Z | - |
dc.date.available | 2018-07-20T07:37:25Z | - |
dc.date.issued | 2017 | - |
dc.identifier.issn | 0028-4793 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/160344 | - |
dc.description.abstract | BACKGROUND: Patients who have residual invasive carcinoma after the receipt of neoadjuvant chemotherapy for human epidermal growth factor receptor 2 (HER2)-negative breast cancer have poor prognoses. The benefit of adjuvant chemotherapy in these patients remains unclear. METHODS: We randomly assigned 910 patients with HER2-negative residual invasive breast cancer after neoadjuvant chemotherapy (containing anthracycline, taxane, or both) to receive standard postsurgical treatment either with capecitabine or without (control). The primary end point was disease-free survival. Secondary end points included overall survival. RESULTS: The result of the prespecified interim analysis met the primary end point, so this trial was terminated early. The final analysis showed that disease-free survival was longer in the capecitabine group than in the control group (74.1% vs. 67.6% of the patients were alive and free from recurrence or second cancer at 5 years; hazard ratio for recurrence, second cancer, or death, 0.70; 95% confidence interval [CI], 0.53 to 0.92; P=0.01). Overall survival was longer in the capecitabine group than in the control group (89.2% vs. 83.6% of the patients were alive at 5 years; hazard ratio for death, 0.59; 95% CI, 0.39 to 0.90; P=0.01). Among patients with triple-negative disease, the rate of disease-free survival was 69.8% in the capecitabine group versus 56.1% in the control group (hazard ratio for recurrence, second cancer, or death, 0.58; 95% CI, 0.39 to 0.87), and the overall survival rate was 78.8% versus 70.3% (hazard ratio for death, 0.52; 95% CI, 0.30 to 0.90). The hand-foot syndrome, the most common adverse reaction to capecitabine, occurred in 73.4% of the patients in the capecitabine group. CONCLUSIONS: After standard neoadjuvant chemotherapy containing anthracycline, taxane, or both, the addition of adjuvant capecitabine therapy was safe and effective in prolonging disease-free survival and overall survival among patients with HER2-negative breast cancer who had residual invasive disease on pathological testing. (Funded by the Advanced Clinical Research Organization and the Japan Breast Cancer Research Group; CREATE-X UMIN Clinical Trials Registry number, UMIN000000843 .). | - |
dc.description.statementOfResponsibility | open | - |
dc.format | application/pdf | - |
dc.language | English | - |
dc.publisher | Massachusetts Medical Society | - |
dc.relation.isPartOf | NEW ENGLAND JOURNAL OF MEDICINE | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Antimetabolites, Antineoplastic/adverse effects | - |
dc.subject.MESH | Antimetabolites, Antineoplastic/therapeutic use | - |
dc.subject.MESH | Breast Neoplasms/drug therapy | - |
dc.subject.MESH | Breast Neoplasms/mortality | - |
dc.subject.MESH | Breast Neoplasms/surgery | - |
dc.subject.MESH | Capecitabine/adverse effects | - |
dc.subject.MESH | Capecitabine/therapeutic use | - |
dc.subject.MESH | Chemotherapy, Adjuvant/adverse effects | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Hand-Foot Syndrome/etiology | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Neoadjuvant Therapy | - |
dc.subject.MESH | Neoplasm Staging | - |
dc.subject.MESH | Preoperative Care | - |
dc.subject.MESH | Receptor, ErbB-2 | - |
dc.subject.MESH | Survival Analysis | - |
dc.subject.MESH | Triple Negative Breast Neoplasms/drug therapy | - |
dc.subject.MESH | Triple Negative Breast Neoplasms/mortality | - |
dc.title | Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine | - |
dc.contributor.department | Dept. of Surgery | - |
dc.contributor.googleauthor | Norikazu Masuda | - |
dc.contributor.googleauthor | Soo-Jung Lee | - |
dc.contributor.googleauthor | Shoichiro Ohtani | - |
dc.contributor.googleauthor | Young-Hyuck Im | - |
dc.contributor.googleauthor | Eun-Sook Lee | - |
dc.contributor.googleauthor | Isao Yokota | - |
dc.contributor.googleauthor | Katsumasa Kuroi | - |
dc.contributor.googleauthor | Seock-Ah Im | - |
dc.contributor.googleauthor | Byeong-Woo Park | - |
dc.contributor.googleauthor | Sung-Bae Kim | - |
dc.contributor.googleauthor | Yasuhiro Yanagita | - |
dc.contributor.googleauthor | Shinji Ohno | - |
dc.contributor.googleauthor | Shintaro Takao | - |
dc.contributor.googleauthor | Kenjiro Aogi | - |
dc.contributor.googleauthor | Hiroji Iwata | - |
dc.contributor.googleauthor | Joon Jeong | - |
dc.contributor.googleauthor | Aeree Kim | - |
dc.contributor.googleauthor | Kyong-Hwa Park | - |
dc.contributor.googleauthor | Hironobu Sasano | - |
dc.contributor.googleauthor | Yasuo Ohashi | - |
dc.contributor.googleauthor | Masakazu Toi | - |
dc.identifier.doi | 10.1056/NEJMoa1612645 | - |
dc.contributor.localId | A03727 | - |
dc.relation.journalcode | J02371 | - |
dc.identifier.eissn | 1533-4406 | - |
dc.identifier.pmid | 28564564 | - |
dc.contributor.alternativeName | Jeong, Joon | - |
dc.contributor.affiliatedAuthor | Jeong, Joon | - |
dc.citation.volume | 376 | - |
dc.citation.number | 22 | - |
dc.citation.startPage | 2147 | - |
dc.citation.endPage | 2159 | - |
dc.identifier.bibliographicCitation | NEW ENGLAND JOURNAL OF MEDICINE, Vol.376(22) : 2147-2159, 2017 | - |
dc.identifier.rimsid | 41520 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.